Overview
The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy.
To determine HRD status, 2 separate tests will be performed in the study:
- Giscar assay : developed by the sponsor
- myChoice assay
If one or two tests identifies a HRD status :
a PARP inhibitor treatment may be initiated according to current recommendations
Eligibility
Inclusion Criteria:
- Patient aged 18-year or more
- Histologically documented high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
- Newly diagnosed advanced (International Federation of Gynecology and Obstetrics [FIGO] stage III or IV) ovarian carcinoma, candidate to a first line platinum-based chemotherapy
- Tumor tissue must be available for HRD analyses (FFPE tissue block) and
- Collected if possible during the initial surgery or the initial biopsy (before chemotherapy)
- With sufficient tumour surface area (> 25 mm²), with a final cellularity of at least 20%
- Patient affiliated to an appropriate social security system
- Patient signed consent form before any trial related activities
Exclusion Criteria:
- Recurrent high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
- Non epithelial or borderline ovarian cancer
- Other tumor, for which the treatment may interfere with the ovarian cancer treatment and/or that may have a major impact on prognosis
- Exclusive palliative setting
- Patient deprived of liberty or placed under the authority of a tutor